PDS Biotechnology director granted 54,876 options

Ali-Jackson Kamil reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Ali-Jackson Kamil reported acquisition or exercise transactions in this Form 4 filing.

PDS Biotechnology Corp director Ali-Jackson Kamil received a grant of 54,876 employee stock options on January 12, 2026. These options are held as direct ownership and were awarded at a reported price of $0.00 per option. The entire grant will vest and become fully exercisable on the first anniversary of the grant date, provided Kamil continues to serve as a director through that date.

Insider Trade Summary

Grant/Award: 54,876 shares

Grant/Award 1 txn

Insider Ali-Jackson Kamil

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	54,876	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Buy) — 54,876 contracts (Direct)

Footnotes (1)

1. F1. The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PDSB director Ali-Jackson Kamil report?

Ali-Jackson Kamil reported receiving a grant of 54,876 employee stock options. The grant was reported at a price of $0.00 per option and represents a new award of derivative securities rather than an open-market purchase or sale of common shares.

When were the 54,876 PDSB stock options granted to Ali-Jackson Kamil?

The 54,876 employee stock options were granted on January 12, 2026. This date starts the one-year vesting clock, after which the options become fully exercisable if the director continues serving on the company’s board through the first anniversary.

How many PDS Biotechnology options does Ali-Jackson Kamil hold after this grant?

After the reported grant, Ali-Jackson Kamil holds 54,876 employee stock options. The filing shows this amount as the total derivative securities beneficially owned following the transaction, all reported as directly owned by the director.

What are the vesting terms of Ali-Jackson Kamil’s 54,876 PDSB stock options?

The 54,876 stock options will vest in full on the first anniversary of the grant date. Vesting is conditioned on Kamil’s continued service as a director of PDS Biotechnology Corp through that one-year anniversary, according to the reported footnote.

Was the PDSB option grant to Ali-Jackson Kamil a buy or sell transaction?

The transaction is classified as an acquisition through a grant or award, not a market buy or sell. It is coded as a Form 4 transaction type “A,” meaning the director received options as compensation rather than trading existing securities.

Is Ali-Jackson Kamil’s ownership of the PDSB options direct or indirect?

The filing reports Ali-Jackson Kamil’s ownership of the 54,876 stock options as direct. The ownership code is “D,” and there is no indication that the options are held through a trust, partnership, or other indirect entity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 06:47 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ali-Jackson Kamil

(Last) (First) (Middle)

C/O PDS BIOTECHNOLOGY CORPORATION

303A COLLEGE ROAD EAST

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PDS Biotechnology Corp [ PDSB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$0.98	01/12/2026		A		54,876		(1)	01/12/2036	Common Stock	54,876	$0	54,876	D

Explanation of Responses:

1. The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date.

	/s/ Spencer Brown, as Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.